Alps Advisors Inc. Invests $512,000 in Kura Oncology, Inc. (KURA) Stock
Alps Advisors Inc. purchased a new position in Kura Oncology, Inc. (NASDAQ:KURA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 33,483 shares of the company’s stock, valued at approximately $512,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Candriam Luxembourg S.C.A. purchased a new position in Kura Oncology in the third quarter worth $8,073,000. Vanguard Group Inc. grew its holdings in Kura Oncology by 13.0% in the second quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock worth $4,035,000 after purchasing an additional 50,033 shares during the last quarter. EAM Investors LLC purchased a new position in Kura Oncology in the third quarter worth $2,884,000. State Street Corp purchased a new position in Kura Oncology in the second quarter worth $1,394,000. Finally, Northern Trust Corp grew its holdings in Kura Oncology by 939.3% in the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock worth $1,372,000 after purchasing an additional 133,293 shares during the last quarter. 63.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of Kura Oncology, Inc. (KURA) opened at $18.50 on Tuesday. Kura Oncology, Inc. has a one year low of $5.90 and a one year high of $21.00. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07. The company has a market cap of $558.99 and a price-to-earnings ratio of -11.94.
WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/02/13/alps-advisors-inc-invests-512000-in-kura-oncology-inc-kura-stock.html.
Kura Oncology Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.